Introduction
Alprolix, recombinant factor IX therapy, a significant player in the treatment of haemophilia B--a rare but severe genetic disorder. Alprolix is doing well in the market, with strong growth. In addition to the popularity of hemophilia, it is benefiting from biopharmaceutical technology which has advanced to long-acting therapeutic options (LAOTs), and there are patients who...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian